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Abstract
Background: There are limited choice of antimicrobial agents to treat infection with metallo- -
lactamase-producing Pseudomonas aeruginosa. We evaluate the antimicrobial effects of aztreonam
alone, colistin alone and the 3-drug combination of aztreonam, ceftazidime and amikacin on 23
strains of metallo- -lactamase-producing P. aeruginosa by time-killing tests.
Methods: Strains used were from different hospitals in Japan and had different pulse-field gel
electrophoresis patterns by restriction with SpeI. The minimum inhibitory concentrations of 11
antimicrobial agents (piperacillin, piperacillin/tazobactam, imipenem, meropenem, aztreonam,
ceftazidime, amikacin, tobramycin, arbekacin, ciprofloxacin and colistin) were determined using the
agar dilution test. The effects of aztreonam, colistin and the combination of aztreonam, ceftazidime
and amikacin were determined by time-killing studies.
Results: Bacteriostatic effects after 6 hours of drug exposure were observed in 12 strains (52.2%)
of 23 strains of metallo- -lactamase-producing P. aeruginosa with 48 mg/l aztreonam, in 19 strains
(82.6%) with the 3-drug combination of 16 mg/l aztreonam, 16 mg/l ceftazidime, and 4 mg/l
amikacin, and in 23 strains (100%) with 2 mg/l colistin. Bactericidal effects after 6 h drug exposure
were observed in 1 strain (4.3%) with 48 mg/l aztreonam, in 8 strains (30.4%) with the 3-drug
combination and in all 23 strains (100%) with 2 mg/l colistin.
Conclusion:  Evaluation of in vitro antimicrobial effects on metallo- -lactamase-producing  P.
aeruginosa revealed relatively good effects of the 3-drug combination of aztreonam, ceftazidime and
amikacin and marked effects of colistin.
Background
Pseudomonas aeruginosa is a major bacterium causing
nosocomial infection, and the development of multidrug
resistance has become a problem [1-7]. Since metallo- -
lactamase (MBL)-producing P. aeruginosa is often resistant
not only to all  -lactams, but also aminoglycosides, and
fluoroquinolones, there are often no drugs to treat infec-
tion with this bacterium [8-10]. In addition, no extended
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survey involving a series of human infections with MBL-
positive isolates has been performed to determine the
optimal treatment. Thus, appropriate therapy for those
infections remains unknown [11].
We previously reported the effects of the 3-drug combina-
tions of aztreonam, ceftazidime and amikacin or aztre-
onam, piperacillin and amikacin on 7 strains of
multidrug-resistant P. aeruginosa [8-10]. In this study, to
confirm the effectiveness of the 3-drug combinations, we
evaluated the effects on a total of 23 strains of MBL-pro-
ducing P. aeruginosa isolated in 23 hospitals in Japan in




Among P. aeruginosa strains sent from hospitals in Japan
to the Japanese National Institute of Infectious Disease for
detailed examination between January 2007 and July
2008, MBL-producing P. aeruginosa strains were screened,
and MBL typing was performed according to the method
of Shibata et al [12]. All 23 strains (one strain/hospital) of
MBL-producing P. aeruginosa isolated during this period
were donated by the Department of Bacterial Pathogene-
sis and Infection Control, National Institute of Infectious
Disease, and used for the experiments.
Pulsed-field gel electrophoresis
The high-molecular-weight chromosomal DNA was pre-
pared according to the method of Murray et al [13], and
the DNA sample in a small slice of an agarose plug in 200
μl of reaction buffer was digested with 30 U SpeI (New
England Bio Labs, USA). Pulsed-field gel electrophoresis
was carried out with the Bio-Rad Gene Path system (Bio-
Rad, USA) in a 1% agarose gel in 0.5 × TBE buffer at 14°C
with a linear ramp time of 1 to 23 s over a period of 18.5
h. Thereafter, the gels were stained with ethidium bro-
mide and photographed.
Susceptibility tests using agar dilution methods
The minimum inhibitory concentrations (MICs) were
determined after 18 h of incubation at 37°C by dilution
on Sensitivity Disc Agar-N (Nissui Pharmaceuticals,
Tokyo, Japan). The following antimicrobial agents were
tested: piperacillin, piperacillin/tazobactam (Toyama
Chemicals, Tokyo, Japan), imipenem, amikacin (Banyu
Pharmaceuticals, Tokyo, Japan), meropenem (Dainip-
pon-Sumitomo Pharmaceuticals, Tokyo, Japan), aztre-
onam (Eisai Co., Tokyo, Japan), ceftazidime (Glaxo Japan
Co., Tokyo, Japan), tobramycin (Shionogi Pharmaceuti-
cals, Tokyo, Japan), arbekacin (Meiji Seika Co., Tokyo,
Japan), ciprofloxacin (Bayer Japan Co., Tokyo, Japan) and
colistin (Wako Junyaku Co., Osaka, Japan). These antibi-
otics except for ciprofloxacin were provided in the form of
a freeze-dried amorphous powder. The inocula (104 col-
ony-forming units [cfu]/spot) were plated using a
multipoint inoculator (Sakuma Co., Tokyo, Japan). The
MIC was defined as the lowest drug concentration that
inhibited visible growth. P. aeruginosa IFO 3919 was used
as the reference strain. The drug concentrations (break-
points) were set as follows: piperacillin, 64 mg/l; imi-
penem and meropenem, 8 mg/l; aztreonam and
ceftazidime, 16 mg/l; amikacin, tobramycin and
arbekacin, 4 mg/l; ciprofloxacin and colistin, 2 mg/l.
Breakpoints used for all agents (except for amikacin,
tobramycin, arbekacin and colistin) were according to the
National Committee for Clinical Laboratory Standards
(NCCLS) criteria [14]. The concentration of amikacin and
tobramycin was 4 mg/l, which is lower than the criteria of
the NCCLS. This was because in Japan, the routine dose of
these agents is lower (ex. in the case of amikacin, 200–400
mg/day in one to two divided doses) than that in Western
countries. The concentration of colistin used was accord-
ing to a report by Soussy et al [15].
Drug effects in killing tests
Killing experiments were carried out to evaluate the bacte-
ricidal activities of 48 mg/l aztreonam, 2 mg/l colistin,
and the 3-drug combination of 16 mg/l aztreonam, 16
mg/l ceftazidime and 4 mg/l amikacin. The final concen-
tration of the log-phase inocula was approximately 105–
107 cfu/ml [16-19]. Viability was determined based on
bacterial counts at 2, 4, 6 and 24 h after incubation with
drugs at 37°C by plating 500 μl of serial dilutions from
each tube onto trypticase soy agar plates followed by incu-
bation of the plates at 37°C for 24 to 48 h. In a prelimi-
nary experiment, drug carryover was ruled out by plating
samples of a bacterial suspension containing 2 × 102– 4 ×
102 cfu/ml in the presence or absence of antimicrobial
agents alone or in combination. We also carried out pre-
liminary killing tests with the 3-drug combination of 16
mg/l aztreonam, 16 mg/l ceftazidime and 4 mg/l ami-
kacin, of 16 mg/l aztreonam, 64 mg/l piperacillin and 4
mg/l amikacin, and of 16 mg/l aztreonam, 64 mg/l piper-
acillin/4 mg/l tazobactam and 4 mg/l amikacin on 23
strains of MBL-producing P. aeruginosa. As a result, the via-
ble cell count at 4 h after drug addition decreased to 1/100
or less of the initial count in 12 strains with aztreonam,
ceftazidime and amikacin, 6 strains with aztreonam, pip-
eracillin and amikacin and 4 strains with aztreonam, pip-
eracillin/tazobactam and amikacin. Thus, the
combination of aztreonam, ceftazidime and amikacin
was the most effective, and therefore, the in vitro antimi-
crobial effects of this drug combination were evaluated.
Bactericidal activity was defined as a ≤ 3 log10 cfu/ml
decrease in the starting inoculum. A bacteriostatic effect
was defined as any decrease in the viable count from the
starting inoculum [17].BMC Infectious Diseases 2009, 9:123 http://www.biomedcentral.com/1471-2334/9/123
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Data analysis
In the killing tests, the effects on the 23 strains of MBL-
producing P. aeruginosa were compared among aztreonam
alone, colistin alone and the three-drug combination of
aztreonam, ceftazidime and amikacin using the Kruskal-
Wallis test based on the decrease in the viable count from
the initial count at 2, 4, 6 and 24 h after drug addition.
Results
Of the 23 MBL-producing P. aeruginosa strains, 1 strain
(strain no. 7) was blaVIM-2, and the other 22 strains were
blaIPM-1 by MBL typing. All 23 strains tested were con-
firmed to differ in their DNA pattern by pulsed-field gel
electrophoresis. Concerning differences in the PFGE pat-
tern, a one band difference was observed in 10 strains of
5 groups, 2–3 band differences in 5 strains of 2 groups,
and more than 3 band differences in the other strains.
Table S1 [additional file 1] shows the MICs of the 11 drugs
against the 23 strains of MBL-producing P. aeruginosa. The
MIC of piperacillin was ≤ 64 mg/l in 16 (69.6%) of the 23
strains. The MIC of piperacillin/tazobactam was ≤ 64 mg/
l in 20 (87.0%), that of aztreonam was ≤ 16 mg/l in 13
(56.5%) and that of colistin was ≤ 2 mg/l in all 23 strains.
However, the MICs of the other antimicrobial agents were
high in most strains.
Aztreonam (48 mg/l) had bacteriostatic effects on 43.5–
56.5% of the strains but bactericidal effects on only 0–
4.3% at 2–24 h after its addition (Table 1, Figure 1). The
3-drug combination of aztreonam (16 mg/l), ceftazidime
(16 mg/l) and amikacin (4 mg/l) had bacteriostatic effects
on 69.6–82.6% of the strains and bactericidal effects on
8.7–39.1% at 2–24 h after their addition (Table 2, Figure
2). On the other hand, colistin (2 mg/l) exhibited bacteri-
cidal effects on all strains (100%) at 2–24 h after its addi-
tion (Table 3, Figure 3). Kruskal-Wallis tests showed
significant decreases in the viable cell count at 2, 4, 6 and
24 h after the addition of colistin (Figure 3) compared
with aztreonam alone (Figure 1) or the 3-drug combina-
tion of aztreonam, ceftazidime and amikacin (Figure 2).
Discussion
No hydrolysis of aztreonam by MBL has been reported,
and studies using an animal model of pneumonia infec-
tion with a VIM-2-positive P. aeruginosa isolate showed
that a high-dose of aztreonam reduced the bacterial load
and may be a useful drug [20,21]. Aztreonam is negligibly
toxic and can be administered at high doses. After high-
dose administration, a blood concentration three times
the breakpoint can be achieved [22].
A 2-drug combination of a  -lactam antibiotic and an
aminoglycoside antibiotic was reported to be effective
against P. aeruginosa [16,19,23-27]. However, for multid-
rug-resistant P. aeruginosa, 3-drug combinations such as
that of aztreonam, ceftazidime and amikacin rather than
2-drug combinations were shown to exhibit more marked
in vitro antimicrobial effects [8,9]. Such observation is
based on experiments in one country. In addition, colistin
is effective in vitro against multidrug-resistant P. aeruginosa
[28-30]. Therefore, we evaluated the bacteriostatic and
bactericidal effects of aztreonam, a 3-drug combination
(aztreonam, ceftazidime and amikacin) and colistin
against 23 strains of MBL-producing P. aeruginosa. We
found that although aztreonam had relatively low MIC (≤
Table 1: Antimicrobial effects of aztreonam (48 mg/l) against 23 
strains of metallo- -lactamase-producing P. aeruginosa
No. of strains (%) showing effectsa
Time of exposure (h) Bacteriostatic effects Bactericidal effects
2 13 (56.5) 0 (0)
4 10 (43.5) 0 (0)
6 12 (52.2) 1 (4.3)
24 11 (47.8) 1 (4.3)
aBacteriostatic effects, any decrease in the viable count from the 
starting inoculum; bactericidal effects, ≥ 3 log cfu/ml decrease in the 
starting inoculum.
Table 2: Antimicrobial effects of the 3-drug combination of 
aztreonam (16 mg/l), ceftazidime (16 mg/l) and amikacin (4 mg/
l) against 23 strains of metallo- -lactamase-producing P. 
aeruginosa
No. of strains (%) showing effectsa
Time of exposure (h) Bacteriostatic effects Bactericidal effects
2 18 (78.3) 2 (8.7)
4 16 (69.6) 5 (21.7)
6 19 (82.6) 7 (30.4)
24 16 (69.6) 9 (39.1)
aBacteriostatic effects, any decrease in the viable count from the 
starting inoculum; bactericidal effects, ≥ 3 log cfu/ml decrease in the 
starting inoculum.
Table 3: Antimicrobial effects of colistin (2 mg/l) against 23 
strains of metallo- -lactamase-producing P. aeruginosa
No. of strains (%) showing effectsa
Time of exposure (h) Bacteriostatic effects Bactericidal effects
2 23 (100) 23 (100)
4 23 (100) 23 (100)
6 23 (100) 23 (100)
24 23 (100) 23 (100)
aBacteriostatic effects, any decrease in the viable count from the 
starting inoculum; bactericidal effects, ≥ 3 log cfu/ml decrease in the 
starting inoculum.BMC Infectious Diseases 2009, 9:123 http://www.biomedcentral.com/1471-2334/9/123
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64 mg/l) among  -lactam antimicrobial agents against 21
of the 23 strains of MBL-producing P. aeruginosa [addi-
tional file 1] the drug at 3-fold the breakpoint concentra-
tion, 48 mg/l, had bactericidal effects only on 1 of the 23
strains when used alone (Table 1).
On the other hand, the 3-drug combination of aztreonam,
ceftazidime and amikacin showed bacteriostatic effects
against 19 (82.6%) of the 23 MBL-producing strains and
bactericidal effects against 7 (30.4%) of the 23 strains at 6
h after drug addition, indicating relatively good in vitro
antimicrobial effects. Therefore, the combination of the 3
drugs should be considered as a treatment method for
infection with MBL-producing P. aeruginosa.
Colistin had more marked in vitro antimicrobial effects
than that of the 3-drug combination against MBL-produc-
ing P. aeruginosa, showing bactericidal effects against all
23 strains at 2–24 h after drug addition. Although colistin
has severe side effects such as renal damage [31,32], some
studies showed the clinical effectiveness of colistin against
multidrug-resistant P. aeruginosa [28,29].
Conclusion
Evaluation of in vitro antimicrobial effects on metallo- -
lactamase-producing  P. aeruginosa revealed relatively
good effects of the 3-drug combination of aztreonam,
ceftazidime and amikacin and marked effects of colistin.
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Table S1 MICs (mg/l) of 11 drugs against 23 strains of metallo-β-
lactamase-producing Pseudomonas aeruginosa. The data provided 
the MICs of the 11 drugs against the 23 strains of MBL-producing P. aer-
uginosa.
Click here for file
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Bactericidal effects of 48 mg/l aztreonam against 23 strains of  metallo- -lactamase-producing P. aeruginosa (37°C) Figure 1
Bactericidal effects of 48 mg/l aztreonam against 23 
strains of metallo- -lactamase-producing P. aerugi-
nosa (37°C).
Bactericidal effects of the 3-drug combination of 16 mg/l  aztreonam, 16 mg/l ceftazidime and 4 mg/l amikacin against  23 strains of metallo- -lactamase-producing P. aeruginosa  (37°C) Figure 2
Bactericidal effects of the 3-drug combination of 16 
mg/l aztreonam, 16 mg/l ceftazidime and 4 mg/l ami-
kacin against 23 strains of metallo- -lactamase-pro-
ducing P. aeruginosa (37°C).
Bactericidal effects of 2 mg/L colistin against 23 strains of  metallo- -lactamase-producing P. aeruginosa (37°C) Figure 3
Bactericidal effects of 2 mg/L colistin against 23 
strains of metallo- -lactamase-producing P. aerugi-
nosa (37°C).BMC Infectious Diseases 2009, 9:123 http://www.biomedcentral.com/1471-2334/9/123
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